In evaluating a child with growth failure, which screening tests are most relevant and cost-effective?

In evaluating a child with growth failure, which screening tests are most relevant and cost-effective?

• A. Tests to determine insulin-like growth factor (IGF-1) levels, CBC, and urinalysis
• B. Bone x-ray films to determine bone age; CBC; T4, TSH, and liver profile tests
• C. Bone x-ray films to determine bone age, CBC, urinalysis, and tests to determine potassium and chloride levels
• D. Tests to determine total protein level, bone x-ray films to determine bone age, urinalysis, and CBC

Answer: (B)

When a child has growth failure, the most useful and cost-effective initial screen looks for common reversible causes and how mature the skeleton is. Getting a bone age with an X-ray of the left hand and wrist provides essential information about skeletal maturation and helps distinguish constitutional delay in growth from endocrine or systemic problems. Alongside this, a few basic labs offer broad screening without driving up costs: a CBC to detect chronic illness or anemia, thyroid function tests (T4 and TSH) to rule out hypothyroidism, and a liver function panel to screen for metabolic or systemic disease. IGF-1 testing, while informative in some contexts, is costly and not typically part of the first-line screen. Urinalysis and electrolyte screens or total protein levels add less value for the initial evaluation of growth failure. The combination of bone age assessment plus CBC, thyroid screening, and liver function tests provides a focused, efficient approach to identify common causes and guide further testing.

When a child has growth failure, the most useful and cost-effective initial screen looks for common reversible causes and how mature the skeleton is. Getting a bone age with an X-ray of the left hand and wrist provides essential information about skeletal maturation and helps distinguish constitutional delay in growth from endocrine or systemic problems. Alongside this, a few basic labs offer broad screening without driving up costs: a CBC to detect chronic illness or anemia, thyroid function tests (T4 and TSH) to rule out hypothyroidism, and a liver function panel to screen for metabolic or systemic disease.

IGF-1 testing, while informative in some contexts, is costly and not typically part of the first-line screen. Urinalysis and electrolyte screens or total protein levels add less value for the initial evaluation of growth failure. The combination of bone age assessment plus CBC, thyroid screening, and liver function tests provides a focused, efficient approach to identify common causes and guide further testing.